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Abstract
Background: Fast, cheap and reliable methods are needed to identify large populations, which
may be at risk in relation to environmental exposure. Polymorphisms in NAT1 (N-acetyl
transferase) may be suitable markers to identify individuals at risk.
Results: A strategy allowing to address simultaneously 24 various genetic variants in the NAT1
gene using the single sequencing reaction method on the same PCR product is described. A
modified automated DNA sequencing using only one of the sequence terminators was used to
genotype PCR products in single-track sequencing reactions of NAT1 and was shown to be
universal for both DNA sequencing using labeled primers and labeled nucleotides. By this method
we detected known SNPs at site T640G, which confers the NAT1*11 allele with frequency of
0.036, further T1088A and C1095A with frequency of 0.172 and 0.188, respectively and a deletion
of TAATAATAA in the poly A signal area with a frequency 0.031. All observed frequencies were
in Hardy Weinberg equilibrium and comparable to those in Caucasian population. The single-track
signatures of the variant genotypes were verified on samples previously genotyped by RLFP.
Conclusions:  The method could be of great help to scientists in the field of molecular
epidemiology of screening of large populations for known informative biomarkers of susceptibility,
such as NAT1.
Background
We have previously described the single sequencing reac-
tion (SSR) protocol for assessment of a known polymor-
phism in the 3'utr region of CYP19  (aromatase) [1,2].
Here we have extended and optimized the use of the
method for multiple polymorphisms in the NAT1 gene.
The increasing number of detected mutations in the
NAT1, makes genotyping using conventional restriction
fragment length polymorphism (RFLP) or allele-specific
amplification complicated. We developed a rapid and
universal strategy based on single-track DNA sequencing
analysis of a unique PCR product encompassing the entire
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NAT1 coding region (contains no introns) along with the
flanking 5' and 3' untranslated regions. It allows a rapid
and economic characterization of NAT1  alleles. Our
method brings reproducible results on both Alf Express™
(Pharmacia) and ABI310 PRISM sequencing instruments
and may be adopted for majority of epidemiological stud-
ies with relevance of NAT1  in environmentally related
diseases.
N-acetyltransferases (NAT, EC 2.3.1.5) are implicated in
the biotransformation of primary arylamines (e.g. 2-
naphthylamine and aminobiphenyls), heterocyclic
amines, hydrazines, and their N-hydroxylated metabolites
present in tobacco smoke and food [3-7]. An increased
activity for p-aminobenzoic acid acetylation (marker for
NAT1 activity) was observed in the breast malignant tis-
sues compared to benign and control tissues [8,9].
Human NATs may have adapted a common catalytic
mechanism from cysteine proteases for acetyl-transfer
reactions [10,11]. The NAT1 gene is highly polymorphic
(for listing of known variant alleles http://www.louis
ville.edu/medschool/pharmacology/NAT.html). Expres-
sion of NAT1*16 but not NAT1*10 and NAT1*11 caused
a 2-fold decrease in the amount and catalytic activity of
NAT1 in COS-1 cell cytosol [12-14]. All available data sug-
gest that slow NAT1 phenotype results from NAT1 allelic
variants that encode reduced expression of NAT1 and/or
less-stable NAT1 protein [15].
Epidemiological studies suggest that the NAT1 and NAT2
acetylation polymorphisms modify the risk of developing
urinary bladder, colorectal, breast, head and neck, lung,
and possibly prostate cancers [16-18]. Interactions
between NAT2*4  and NAT1*10  were suggested by the
increased frequency of the NAT2*4/NAT1*10 haplotype
[19-21]. The individual risks associated with NAT1
acetylator phenotypes/genotypes are usually small, but
they increase when considered in conjunction with other
susceptibility genes and/or aromatic and heterocyclic
amine carcinogen exposures. Because of the relatively
high frequency of the variant NAT1 genotypes in the pop-
ulation, the attributable cancer risk may be high. Large-
scale molecular epidemiological studies that investigate
the role of NAT1 genotypes and/or phenotypes together
with other genetic susceptibility gene polymorphisms and
biomarkers of carcinogen exposure are necessary to
expand our current understanding of the role of NAT1
acetylation polymorphisms in cancer risk [22].
Results
We outlined a strategy allowing to address simultaneously
13 genetic variants in the coding area of NAT1 with two
sequencing tracks: A and G and 11 variants in the 3' flank-
ing area with two tracks: A and T (Table 1). Using single-
track sequencing of the NAT1  coding region, we have
detected 11 individuals carrying polymorphisms at site
T640G, which characterizes NAT1*11  alleles (Figure
1C,1D,1E). Identical results were obtained when perform-
ing the single-track sequencing on an Alf Express™ system
as on ABI310 PRISM (Figure 2E,2F). The frequency of this
polymorphism, 0.036 found by single-track sequencing in
our study was comparable to the frequency 0.032 found
by PCR-RFLP method in 396 German control individuals
[23]. Polymorphisms T1088A  and  C1095A  (Figure
3A,3B,3C and Figure 4A,4B,4C, representing each geno-
type analyzed by both Alf Express™ and ABI310 PRISM)
were in perfect linkage disequilibrium. The frequency of
these polymorphisms was 0.172 and 0.188 respectively
and was comparable to frequency 0.206 reported by
Bruhn et al. [24].
A-track sequencing of the 3'-untranslated region of NAT1
revealed a deletion of TAATAATAA (Figure 3D,3E on Alf
Express™ and Figure 4E on ABI310 PRISM). It was found
in 7 individuals accounting for the frequency 0.031,
which is comparable to the frequency 0.033 observed in
the study on 314 control individuals by Bruhn et al. [24].
Table 1: Overview of NAT1 alleles and selection for single-track 
sequencing
coding region: track/ddNTP allele
350,351 GG → CC G NAT1*5
402 T → CT NAT1*20
445 G → AG NAT1*11
459 G → AG NAT1*11
497–499 GGG → CCC G NAT1*5
559 C → TT NAT1*15
560 G → AG NAT1*14
613 A → GG NAT1*21
640 T → GT / G NAT1*11
752 A → TT NAT1*22
777 T → CT NAT1*23, *27
781 G → AG NAT1*24
787 A → GG NAT1*25
poly A region: track/ddNTP allele
884 A → GA NAT1*5
976 delA A NAT1*5
1025 delT T NAT1*29
1067–1090 delTAATAATAA A NAT1*11
1067–1090 delTAATAA A NAT1*28
1067–1090 delTAA A NAT1*18
1067–1090 insTAA A NAT1*26
1088 T → AA NAT1*10, *14,
NAT1*18, *29
1091 ins AAA A NAT1*16
1095 C → AA NAT1*3, *10, *11,
NAT1*14,*16,*18,
NAT1*26, *29
1105 delT T NAT1*5BMC Biotechnology 2004, 4:28 http://www.biomedcentral.com/1472-6750/4/28
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Genotyping of the coding region of NAT1 by T-track sequencing on Alf Express™ Figure 1
Genotyping of the coding region of NAT1 by T-track sequencing on Alf Express™. (A) Displayed area from T382 to T417 (B) 
Displayed area from T531 to T582 (C) Displayed area from T618 to T661, with genotypes 640T/T; (D) 640T/G; (E) 640G/G; (F) 
– Displayed area from T735 to T797, A752T and T777C alleles not found.BMC Biotechnology 2004, 4:28 http://www.biomedcentral.com/1472-6750/4/28
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NAT1 variants in the coding region assessed by G-track sequencing on ABI310 PRISM Figure 2
NAT1 variants in the coding region assessed by G-track sequencing on ABI310 PRISM. (A) Displayed area from G418 to G476, 
genotypes 445G/G and 459G/G; (B) 445G/A and 459G/A heterozygote; (C) Displayed area from G544 to G590, genotypes 
560G/G; (D) 560G/A; (E) Displayed area from G598 to G655, genotypes 613A/A and 640T/T; (F) 613A/A and 640A/G.BMC Biotechnology 2004, 4:28 http://www.biomedcentral.com/1472-6750/4/28
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NAT1 alleles in 3'-untranslated region assessed by single A-track sequencing on Alf Express™ Figure 3
NAT1 alleles in 3'-untranslated region assessed by single A-track sequencing on Alf Express™. Displayed area from A1038 to 
A1104. (A) NAT1*4/*4 – wild type; (B) 1088T/A and 1095C/A heterozygote; (C) 1088A/A and 1095A/A homozygote; (D) 
NAT1*4/*11 allele; (E) NAT1*11/*11 allele.BMC Biotechnology 2004, 4:28 http://www.biomedcentral.com/1472-6750/4/28
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NAT1 alleles in 3'-untranslated region by single A-track sequencing on ABI310 PRISM Figure 4
NAT1 alleles in 3'-untranslated region by single A-track sequencing on ABI310 PRISM. Displayed area from A1104 to A1048. 
(A) NAT1*4/*4 – wild type; (B) 1088T/A and 1095C/A heterozygote; (C) 1088A/A and 1095A/A homozygote; (D) 1088T/T 
homozygote and 1095C/A heterozygote; (E) NAT1*4/*11 allele.BMC Biotechnology 2004, 4:28 http://www.biomedcentral.com/1472-6750/4/28
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This change is also unique for the NAT1*11 alleles and co-
segregates with T640G polymorphism. Very good co-seg-
regation of T640G  and 1067-1090delTAATAATAA  poly-
morphisms in 7 informative samples was observed (4
heterozygotes and 3 homozygotes). Despite the different
chemistry, Figures 1, 2, 3, 4 demonstrate perfect concord-
ance between the results obtained by Alf Express™ and
ABI310 PRISM analysis, verified on samples with previ-
ously characterized genotypes by RFLP.
Discussion
A modified automated DNA sequencing with a fluores-
cent label was used to genotype PCR products spanning
through the whole NAT1 gene by single-track sequencing
reactions in 192 control individuals. Previously, we have
shown that single-track sequencing reactions performed
on PCR products, with subsequent analysis on an Alf
Express™ DNA Sequencer, can be as informative, sensitive,
and accurate as complete sequencing reactions but more
economical option for the genotyping of known polymor-
phisms in the human aromatase gene [1]. Compared to
analysis by full gel-based sequencing, four times more
samples can be analyzed per gel in considerably shorter
time. The method could be particularly efficient in cases
of high density of polymorphic sites residing in a com-
mon area as in the case of NAT1.
Conclusions
This paper shows that single-track sequencing reactions
can be used as a tool for screening for all types of known
polymorphisms in field laboratories with limited or over-
loaded sequence capacity. Compared to standard
sequencing, this single track sequencing may have better
signal to noise ratio. This approach is time and cost effec-
tive and can be accommodated for high-throughput anal-
yses in epidemiology studies.
Methods
Materials
Chemicals for PCR and sequencing were purchased from
ABI (Applied Biosystems, Foster City, CA, USA) and
Amersham Biosciences (Uppsala, Sweden).
Subjects
The study included 192 DNA samples from Norwegian
healthy individuals obtained through Norwegian Popula-
tion Registry as a population-based series of residents in
the Oslo area. Test samples from healthy Norwegian con-
trols with known genotypes (previously assessed by RFLP)
were available.
PCR amplification of NAT1
A single PCR amplification of the entire coding region and
the 3' flanking area of NAT1  (923 bp) using forward
primer: 5'-tactgggctctgaccactat-3' and reverse primer: 5'-
tgctttctagcataaatcacc-3' was performed. PCR mix con-
tained 16.9 µl dH2O, 10 × PCR buffer (2.5 µl), 1.25 mM
MgCl2 (4 µl), 2.0 mM dNTP (1.0 µl mixture of each), 10
µM oligonucleotide primer, 0.2 µl Taq DNA polymerase
(Perkin Elmer, 5 U/µl) and 1.0 µl of genomic DNA (100
ng/µl) in a final volume of 25 µl. Thermal cycling (Gene-
Amp 2400, PE, Foster city, CA) included initial denatura-
tion 2 min at 94°C, 10 cycles of 30 sec at 94°C, 30 sec at
decreasing annealing temperature 58 to 48°C, 1 min at
72°C, and 25 cycles of 30 sec at 94°C, 30 sec at 50°C and
1 min at 72°C. Quality of PCR products was checked on
6% acrylamide gels.
Single-track sequencing
The SNPs studied by this assay are summarized in Table 1.
Single A-, G- and T- track sequencing using 1 given termi-
nator at a time was performed using both Alf Express™ sys-
tem (Pharmacia Biotech, Uppsala, Sweden) and ABI310
PRISM capillary sequencer. Alf Express™ Cy5-labeled
primers NAT1A-F-CY5: 5'-gggagggtatgtttacagca-3' and
NAT1A-POLYA-CY5: 5'-gcataaatcaccaatttcca-3' were used
for genotyping the coding region and 3'untranslated area
of NAT1, respectively. The single sequencing reactions (7
µl) contained: 1.25 µl of dH2O, 0.5 µl of 10-times concen-
trated FS polymerase buffer (125 mM Tris-HCl, pH 9.5, 50
mM (NH4)2SO4, 150 mM MgCl2), 2 µl of ddNTP termina-
tion mix (containing 10 mM dNTPs and either ddATP or
ddTTP (10 µM) for A-track or T-track sequencing respec-
tively, 1 µl of 2 µM primer, 0.25 µl of FS polymerase (5 U/
µl), and 2 µl of NAT1 PCR product. The following condi-
tions were used for thermal cycling: initial denaturation
for 5 min at 95°C, 35 cycles of 30 sec at 95°C, 30 sec at
50°C, and 1 min at 68°C. The single-tracks were evalu-
ated using conventional software AlfWin, Fragment Ana-
lyzer, v. 1.02 supplied with the sequencer (Alf Express™).
For the single-track sequencing by ABI310 PRISM we used
the same sequencing primers as for Alf Express™ system
however labeled with the fluorophor 6-FAM. Sequencing
reactions (10 µl) contained: 5.0 µl dH2O, 1.0 µl of 10-
times concentrated Thermo Sequenase buffer (260 mM
Tris-HCl, pH 9.5, 65 mM MgCl2), 2.0 µl of ddNTP termi-
nation mix (containing dNTPs and either ddATP or
ddGTP for A-track or G-track sequencing respectively – for
composition see Table 3), 0.5 µl of 1 µM primer, 0.5 µl of
Thermo Sequenase DNA polymerase (with pyrophos-
phatase) 3.2 U/µl and 1.0 µl  NAT1  PCR product
(described above). Thermal cycling conditions were as fol-
lows: initial denaturation 20 sec at 95°C, 25 cycles of 20
sec at 95°C, 20 sec at 55°C and 1 min at 72°C, and then
10 cycles of 20 sec at 95°C, 1 min at 72°C. Results were
evaluated using GeneScan Analysis software, v. 3.7.
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